Atorvastatin cost effective in T2DM
- PDF / 186,363 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 57 Downloads / 228 Views
PharmacoEconomics & Outcomes News 861, p6 - 5 Sep 2020 Atorvastatin cost effective in T2DM Atorvastatin is cost effective in patients with type 2 diabetes mellitus (T2DM) but omega-3 acid ethyl esters [omega-3 fish oil; Omacor; Pronova BioPharma Norge] is not cost effective, according to findings of a cost-utility analysis published in Value in Health. The UK Prospective Diabetes Study Outcomes Model version 2.01(UKPDS-OM2), populated with 16-week data from the cluster-randomised, placebo-controlled, 2 x 2 x 2 factorial AFORRD (Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes) trial conducted in 800 patients with T2DM in UK general practices, was used to evaluate the cost effectiveness of atorvastatin, omega-3 fish oil and an action-planning leaflet, alone and in combination, compared with no treatment. Cost effectiveness was assessed from the UK National Health Service (NHS) perspective over a 70-year time horizon. In the base-case 2 x 2 analysis, atorvastatin monotherapy dominated (more effective and less costly) no treatment, with an incremental gain of 0.268 QALYs and cost savings of £262 (p
Data Loading...
